Purchase this article with an account.
A. Babayan Sosa, A. Levine, S. Rojas, R. García, E. Lopez; Efficiency and Security of Intravitreal Triamcinolone for the Treatment of Pars Planitis . Invest. Ophthalmol. Vis. Sci. 2003;44(13):2411.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Purpose: To determine the efficiency and security of intravitreal triamcinolone for the treatment of pars planitis. Material and Methods: We included patients with clinical diagnosis of pars planitis that agreed to participate in the study. Triamcinole (4 mg/0.1 ml) was injected into the vitreous chamber in the operating room. Follow up was made for three months where the inflammations signs, visual acuity, ocular tension and complications were recorded. Results: Four patients were included with a mean age of 11.7 years. Inflammation in the anterior chamber was controlled in the first two weeks after treatment, while the posterior chamber inflammation decreased between 1 and 2 months after treatment . Two patients had ocular hipertension, one requiring surgery for its control. Conclusion: Intravitreal triamcinolone may be effective to control inflammation in patients with pars planitis, but there is a high risk for ocular hipertension.
This PDF is available to Subscribers Only